3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
86
Leukemia
50
Gastrointestinal Stromal Tumors
41
Leukemia, Myeloid, Chronic-Phase
28
Precursor Cell Lymphoblastic Leukemia-Lymphoma
25
Blast Crisis
17
Philadelphia Chromosome
13
Brain Neoplasms
12
Sarcoma
10
Leukemia, Myeloid, Acute
10
Glioblastoma
10
Lung Neoplasms
9
Leukemia, Myeloid, Accelerated Phase
9
Gliosarcoma
9
Prostatic Neoplasms
8
Neoplasms
7
Neoplasm Metastasis
7
Glioma
7
Oligodendroglioma
6
Melanoma
6
Leukemia, Myelomonocytic, Chronic
6
Dermatofibrosarcoma
6
Astrocytoma
6
Small Cell Lung Carcinoma
5
Recurrence
5
Primary Myelofibrosis
5
Polycythemia Vera
5
Ovarian Neoplasms
5
Leukemia, Myeloid
5
Central Nervous System Neoplasms
5
Interventions
Ipilimumab
16
incomplete Freund's adjuvant
9
Nivolumab
9
sargramostim
6
Temozolomide
6
Dacarbazine
6
montanide ISA 51
5
MART-1 Antigen
5
Blood Specimen Collection
5
pembrolizumab
4
Ranibizumab
4
Melphalan
4
Interleukin-2
4
Carboplatin
4
CTLA-4 Antigen
4
Thalidomide
3
Surveys and Questionnaires
3
MAGEA3 protein, human
3
Granulocyte-Macrophage Colony-Stimulating Factor
3
AZD 6244
3
sotrastaurin
2
relatlimab
2
gp100 Melanoma Antigen
2
fludarabine phosphate
2
fludarabine
2
entinostat
2
aflibercept
2
Taxes
2
Sunitinib
2
Sorafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Uveal Melanoma
×
Imatinib Mesylate
×
Clear all
NCT01046487
2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1
Completed
26 enrolled